In short
This article discusses a clinical trial investigating the use of Doconexent, a component of a fat emulsion, in pediatric patients with Long-chain Fatty Acid Oxidation Disorders (LC-FAOD). The study aims to compare the effects of triheptanoin, which contains Doconexent, with medium-chain triglycerides (MCT) on major clinical events in children with LC-FAOD. This research is crucial for understanding potential treatments for this rare metabolic condition.
At a glance
- Study Type
- Randomized, double-blind, multicenter study
- Participants
- Pediatric patients (0 to <18 years) with LC-FAOD
- Intervention
- Triheptanoin (containing Doconexent) vs. Medium-chain Triglycerides (MCT)
- Primary Outcome
- Annualized rate of Major Clinical Events (MCEs)
- Secondary Outcomes
- Duration of MCEs, hypoglycemic events, cardiomyopathy events, quality of life measures
- Treatment Duration
- Up to 24 months
- Additional Component
- Liver Sub-study for participants >2 years old
What is DOCONEXENT?
DOCONEXENT, also known as docosahexaenoic acid or DHA, is a type of omega-3 fatty acid that is being studied as a potential treatment for children with Long-chain Fatty Acid Oxidation Disorders (LC-FAOD). It is part of a combination medication that includes other substances such as glycerol, icosapent (another omega-3 fatty acid), egg lecithin, and vitamin E (DL-alpha-tocopherol).
What are Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)?
Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) are a group of rare genetic conditions that affect how the body breaks down fats for energy. People with LC-FAOD have difficulty converting long-chain fatty acids into energy, which can lead to various health problems, especially during times of illness, fasting, or increased energy demands.
Some types of LC-FAOD include:
- Carnitine palmitoyl transferase (CPT) I deficiency
- CPT II deficiency
- Carnitine/acylcarnitine translocase (CACT) deficiency
- Very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency
- Long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency
- Mitochondrial trifunctional protein (TFP) deficiency
Clinical Trial Overview
A clinical trial is being conducted to evaluate the effectiveness of a medication containing DOCONEXENT (along with other substances) compared to medium-chain triglycerides (MCT) in children with LC-FAOD. This study is:
- Randomized: Participants are randomly assigned to either the DOCONEXENT group or the MCT group
- Double-blind: Neither the participants nor the researchers know which treatment each child is receiving
- Multicenter: The study is being conducted at multiple hospitals or research centers
Who Can Participate in the Study?
The study is designed for children with LC-FAOD. Some key eligibility criteria include:
- Children from birth to less than 18 years old
- Confirmed diagnosis of LC-FAOD
- Significant clinical symptoms of LC-FAOD, such as:
- At least 2 severe episodes in the past year (or 3 in the past 2 years) requiring emergency care or hospitalization
- Recurrent symptomatic hypoglycemia (low blood sugar)
- Susceptibility to hypoglycemia after short fasting periods
- Evidence of heart problems (cardiomyopathy) requiring ongoing medical management
There are additional criteria for participation, and some conditions may exclude a child from the study. It's important to discuss with your doctor if you think your child might be eligible.
Study Objectives
The main goal of this study is to evaluate how well the DOCONEXENT-containing medication works compared to MCT in reducing the frequency of major clinical events (MCEs). MCEs are serious health problems that can occur in children with LC-FAOD, such as:
- Rhabdomyolysis: A condition where muscle tissue breaks down rapidly, which can be dangerous for the kidneys
- Cardiomyopathy: Heart muscle disease that can affect the heart's ability to pump blood effectively
- Hypoglycemia: Dangerously low blood sugar levels
The study will also look at other important factors, such as:
- How long these major clinical events last
- Changes in overall health status and functioning
- Effects on heart function
- Impact on quality of life
- Safety of the medication
Potential Benefits of DOCONEXENT
While the study is still ongoing and results are not yet known, researchers hope that the DOCONEXENT-containing medication may offer several potential benefits for children with LC-FAOD, such as:
- Reducing the frequency and duration of major clinical events
- Improving overall health and functioning
- Reducing the frequency of hypoglycemic events
- Potentially improving heart function in children with cardiomyopathy
- Enhancing quality of life for children with LC-FAOD and their families
Safety Considerations
As with any medical study, there are important safety considerations to keep in mind:
- The study will carefully monitor for any side effects or adverse events
- Participants will be closely followed by medical professionals throughout the study
- Some children may not be eligible to participate if they have certain medical conditions or are taking specific medications
- The study drug's long-term effects are not yet fully known
It's crucial for parents and caregivers to discuss all potential risks and benefits with their child's doctor before considering participation in this or any clinical trial.